28903 North Avenue Paine
United States - Map
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes patients in the United States. Its approved product is AFREZZA, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. MannKind Corporation has license and collaboration agreement with Sanofi-Aventis Deutschland GmbH for the development of AFREZZA. The company was founded in 1991 and is headquartered in Valencia, California.
|MannKind Corp.’s ISS Governance QuickScore as of Apr 1, 2016 is 6. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 3; Compensation: 7.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Matthew J. Pfeffer CPA,
Chief Exec. Officer and Chief Financial Officer
|Mr. Alfred E. Mann ,
Founder and Chairman Emeritus
|Mr. Joseph Kocinsky ,
Chief Technology Officer and Corp. VP
|Dr. David B. Thomson Ph.D., J.D.,
Corp. VP, Gen. Counsel and Corp. Sec.
|Ms. Rosabel Realica Alinaya ,
Principal Accounting Officer and Sr. VP of Fin.
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|